Quick Answer
Petros Pharmaceuticals, Inc. reported Operating Income of -$17.68 million for fiscal year 2024.
Petros Pharmaceuticals, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2024 | -$17.68M | -29.8% |
| 2023 | -$13.62M | +31.6% |
| 2022 | -$19.92M | -10.3% |
| 2021 | -$18.05M | -4.4% |
| 2020 | -$17.28M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$990.7K | +17.3% | +45.0% |
| June 30, 2025 | -$1.80M | -33.5% | -23.5% |
| March 31, 2025 | -$1.46M | +3.0% | -21.8% |
| September 30, 2024 | -$1.20M | +75.1% | +11.2% |
| June 30, 2024 | -$1.35M | +45.2% | +10.2% |
| March 31, 2024 | -$1.50M | -14.8% | +68.7% |
| September 30, 2023 | -$4.81M | +64.8% | -95.2% |
| June 30, 2023 | -$2.46M | -48.2% | -88.1% |
- Petros Pharmaceuticals, Inc. showed a decrease of -29.8% in Operating Income compared to the prior fiscal year.
- Over the 2020–2024 period, Petros Pharmaceuticals, Inc.’s operating income has declined by 2.3% (from -$17.28 million to -$17.68 million).
- The most recent figure is from Petros Pharmaceuticals, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: